Issue link: http://deals.uberflip.com/i/1519691
Comprehensive Vein Procedure Clinic #61786 DISCLAIMER: All information contained in this document has been provided by the subject company to Generational Equity and while believed to be correct has not been verified. Accordingly, Generational Equity makes no representations or warranties as to the accuracy and truthfulness of such information. The recipient hereof acknowledges that Generational Equity shall not be liable for any loss or injury suffered by said recipient in any way connected to the delivery by Generational Equity of this document. At all times Generational Equity and its affiliate network members is an agent for the seller and not for the buyer. Generational Equity's fees are paid by the seller. Tom Staszak Managing Director Email: tstaszak@generational.com Office: (813) 451-1972 Generational Group Client#: 67092 NDA Link: NDA 67092 Business Summary This Company is the largest and most comprehensive vein and vascular center in its region. It is the premier provider of vein disorders diagnosis and treatment. Using a variety of treatment op ons, the Company is able to resolve vein and vascular issues and help pa ents return to a life free from pain. The Company treats vein disorders ranging from superficial vein disease treated in the office to complex treatment of deep veins or pelvic veins in the hospital or an outpa ent surgery center. Although in the past the center treated cardiac, arterial vascular, and vein disorders, vein disorders are now its primary focus. In office vein treatments generate 100% of the company's revenue. Cardiac and arterial disorders are now referred to colleagues for treatment. INVESTMENT APPEAL • Long-Tenured Knowledgeable Staff: To ensure pa ents receive the highest quality treatment, the Company's staff a end and par cipate in many scien fic medical mee ngs each year, and are regular contributors to medical literature. • Nearly Unlimited Growth Poten al: Among other vein issues, the Company treats Chronic Venous Insufficiency (CVI) which is es mated to occur in 1 out of 4 adults over the age of 50. As a contributor to heart health, CVI is a rapidly-growing field of which, this Company is a leader. • Historical Sales Growth: Historical sales have grown from $1.65 million in 2021 to $3.37 million in 2023, represen ng a compound annual growth rate of 42.8%. Sales have grown consistently year over year during the historical period. Available for Acquisi on Central U.S. Opera ons 2024 Revenue Est. $4,200,000 2024 EBITDA Est. $2,600,000 INVESTMENT BANK OF THE YEAR Historical & Pro Forma EBITDA ($000)